Loading news...
Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) is drawing fresh attention to its experimental cancer therapy azer-cel after a Channel 10 news report highlighted...
Dimerix Ltd (ASX:DXB, OTC:SBMJF) has completed dosing the last adult patient in its ACTION3 Phase 3 trial of DMX-200 for focal segmental glomerulosclerosis...
Clinical-stage immuno-oncology company Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has reported encouraging early response rates from the CAR T-naïve cohort...
Pantoro Gold Ltd (ASX:PNR, OTC:PNTOF, FRA:RKN) has reported higher revenue and earnings for the first half of FY2026, supported by gold production of 41,623...
Dimerix Ltd (ASX:DXB, OTC:SBMJF) has flagged that its US commercial licensing agreement for DMX-200 remains intact following BioMarin Pharmaceutical’s move...
Recruitment successfully completed in Dimerix' ACTION3 Phase 3 clinical trial[1], which has recruited and dosed its target 286th adult patient The ACTION3